Risperidone is a widely used atypical antipsychotic with certain advantages over typical antipsychotics. Although variations in the efficacy of treatment with risperidone have been observed, no specific predictable marker has been identified as of yet. In all, 73 Japanese patients with schizophrenia were given risperidone for 8 weeks, and clinical symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS). Six candidate polymorphisms (HTR2A À1438G4A, 102T4C, H452Y; DRD2 À141delC, Taq I A; COMT V158M) were genotyped. The diplotype configuration for each individual was estimated by the maximum-likelihood method. Multiple linear regressions were used to analyze the effects of these haplotypes/genotype and other prognostic factors on PANSS scale performance. After adjustment for the effects of patient-related variables, HTR2A diplotype and COMT genotype, as well as other potential prognostic factors, did not significantly influence the clinical performance. A DRD2 haplotype tended to correlate with better clinical performance. Compared with patients who had Ins-A2/Ins-A2 diplotype (n¼25), PANSS total scores of patients with Ins-A2/ Del-A1 diplotype (n¼10) showed 40% greater improvement (P¼0.03). The PANSS total scores of patients with HTR2A A-T/A-T diplotype (n¼22) tended to show 15% worse improvement compared with A-T/G-C diplotype (n¼33) (P¼0.06). These results should be treated with caution because of limitations due to small sample size, heterogeneity of patients with respect to past antipsychotic use history, and no correction for multiple corrections. However, the present findings generate important hypotheses in a sample of Japanese schizophrenia patients that may lay the foundation for future pharmacogenomics investigations in other populations.
INTRODUCTION
Risperidone, one of the most widely used atypical antipsychotics, has two major advantages over typical antipsychotics: (1) high efficacy in the treatment of negative symptoms of schizophrenia and (2) a few side effects.
1 Dopamine D2 receptor blockade is thought to mediate antipsychotic action, while the blocking of serotonin 2A receptor has been implicated in its added efficacy as well as its reduced extrapyramidal side effects profile. 2 Recent studies reported that certain polymorphisms in the dopamine D2 receptor gene (DRD2) and the serotonin 2A receptor gene (HTR2A) are associated with schizophrenia or antipsychotic drug responses. For example, DRD2 À141delC 3 and Taq I A 4 polymorphism caused a functional change of the product, and both are reported to have an association with antipsychotic response. 5, 6 HTR2A 102T4C polymorphism showed an association with the presence of schizophrenia, 7 and À1438G4A polymorphism with a clozapine response. 8 In addition, HTR2A H452Y polymorphism, which caused a functional change of the expressed gene product, 9 is reported to be involved in clozapine response. 10 Very recently, Lane et al 11 reported a significant association between HTR2A 102T4C polymorphism and risperidone efficacy for negative symptoms in Chinese Han patients. However, the interaction between DRD2 and HTR2A to risperidone efficacy has not been explored by pharmacodynamic-pharmacogenetics studies.
Moreover, a common functional polymorphism in the human catechol-O-methyltransferase gene (COMT), a methylation enzyme that metabolizes released dopamine, which accounts for a four-fold variation in enzyme activity and dopamine catabolism, was shown to be associated with cognitive characteristics that are presented in schizophrenia. 12 Shifman et al 13 recently reported a highly significant association between schizophrenia and a COMT haplotype. The biological functions of COMT, in addition to the genetic association findings, make it a popular candidate because of the long-hypothesized role of dopamine in schizophrenia. 14 To explicate the variability of risperidone response from one individual to another using pharmacodynamic-pharmacogenetics approach, we investigated whether DRD2, HTR2A, and COMT genes associate with risperidone effectiveness.
RESULTS

Of 73
Japanese schizophrenic patients, 33 were newly administered risperidone as a first-time prescription, and 40 consisted of a group that was switched from typical antipsychotics. There were no differences between the two groups for gender, age, and mean dose of risperidone at 8 weeks. Durations of illness and hospitalization as well as initial mean total score of the Positive and Negative Syndrome Scale (PANSS) varied, because most of the newly administered patients were experiencing their first episode of illness and had been previously untreated (Table 1) .
The proportions of genotype at each site were consisted in the Hardy-Weinberg equilibrium among each group. There were no differences in genotypes and frequencies of each polymorphism between New Group and Switched Group (Table 2) . Therefore, we combined the two groups together following analysis. HTR2A H452Y polymorphism was excluded in further analysis because all subjects were H/H homozygote genotypes in our samples. Allele frequencies of the six polymorphisms were similar to those calculated from reported data of Japanese populations, suggesting that our data was not biased with respect to allele frequency. [5] [6] [7] Because À141delC and Taq I A (DRD2), À1438G4A and 102T4C (HTR2A) polymorphisms exist in the same gene loci, one of these two polymorphisms would be actually related to risperidone treatment response, and another might be in linkage disequilibrium. Using in silico methods, the haplotype configuration for each locus could be estimated. Subsequently, the diplotypes of DRD2 and HTR2A were used for further analyses. The genotypic findings from all patients were analyzed using the computer programs Haplotyper, 15 EMDecoder, 15 and PHASE 16 to estimate haplotype frequencies concerning the two-polymorphism DRD2 and HTR2A loci. The three programs estimated identical individual haplotype estimation. The estimated haplotype frequencies were not deviated from the maximum likelihood estimation. Table 3 indicates the number of individuals, with each diplotype configuration for the DRD2 (a) and HTR2A (b) loci. Two polymorphisms in HTR2A were in complete linkage disequilibrium, as in previous studies. [17] [18] [19] The distribution of the PANSS total and subscale scores was skewed to the right (data not shown) and unsuitable for regression analyses. The value of each score was thus transformed to its natural logarithm to obtain normal distributions (data not shown). Table 4 illustrates the effects of DRD2, HTR2A, and COMT genes on antipsychotic response to risperidone after adjustment for the effects of treatment-related and patient-related some typical antipsychotics, which might affect the dopamine D2 receptor expression. Second, the sample size was so small (n¼73) that the power of analysis was reached at 0.55 (when a¼0.05) and the least significant number was 104, which is the minimum number of samples needed. Third, we did not correct the statistical findings for multiple comparisons. We performed 15 paired multiple comparisons for evaluate the total PANSS sores. It is controversial that À141delC and Taq I A polymorphisms affect the density of the dopamine D2 receptor. With regard to the À141delC polymorphism, positron emission tomography studies that explored genotypes with the Del allele that were associated with increased density of the receptor at human striatum have yielded conflicting results. 20, 21 As for the Taq I A polymorphism, the genotype with homozygous A1 allele was reported to be associated 
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New group compared to switched group with decreased density of the receptor; [22] [23] [24] [25] however, other studies failed to show the correlation. 26 Further investigations are needed to explain which haplotype affects the D2 receptor expression.
HTR2A diplotype compared to A-T/G-C (n¼33)
Our results did not support the HTR2A positive findings by Lane et al. 11 First, we combined the two groups because the proportion of genotype frequencies did not differ. Although risperidone exhibits a high affinity for both serotonin 2A receptor and dopamine D2 receptors, the desensitization effects may be different by the previous typical antipsychotic use. Second, a small number of subjects may cause statistical beta errors. Indeed, the power to detect the PANSS total score for HTR2A diplotype was 0.37 (when a¼0.05) and the least significant number was 130, which is the minimum number of samples needed to thoroughly evaluate our negative findings. However, compared with patients who had A-T/G-C diplotype (n¼33), the PANSS total scores of patients with A-T/A-T diplotype (n¼22) tended to show 15% worse improvement (P¼0.06). The favorable tendency of the allele C-C, that is the same inference G-C/G-C diplotype because of complete linkage disequilibrium, was observed in our samples. DRD2 and HTR2A genes are both putative biological targets for risperidone. It is possible that an analysis for epitasis may unmask the important joint contributions by these two genes. The contribution of HTR2A can potentially be unmasked when viewed within the context of DRD2.
In this pilot study, we generate important hypotheses in a sample of Japanese schizophrenia patients that may lay the foundation for future pharmacogenomics investigations in other populations and other candidate genes, such as the dopamine D4 receptor. 27 
SUBJECTS AND METHODS
Subjects
The subjects were 61 patients with schizophrenia and 12 patients with schizophreniform disorder, who lived in the central part of Japan. Consensus diagnosis according to DSM-IV by at least two experienced psychiatrists was made with double-blind evaluation for each patient on the basis of unstructured interviews and information from medical records. None had severe medical complications or other Axis-I disorders according to DSM-IV. All patients were unrelated to each other and ethnically Japanese. After description of the study, written informed consent was obtained from each subject. This study was approved by the Ethics Committee of the Fujita Health University.
Clinical Protocols
Subjects received only risperidone as antipsychotic treatment for 8 weeks. No other drugs were given, except benzodiazepine and barbiturate for insomnia, anticholinergic drugs for extrapyramidal symptoms, and less than 50 mg/day levomepromazine for agitation or excitement. The subjects belonged to either the 'new group', comprised of subjects who took an antipsychotic for the first time or had not received any antipsychotics for at least 1 month before this study, or the 'switched group', which consisted of subjects asked to change antipsychotic drugs from typical antipsychotics to risperidone. The subjects who belonged to the 'new group' took 2-6 mg/day of risperidone. Those who belonged to the 'switched group' were administered their former drugs for at least 4 weeks. After this period, antipsychotics were gradually replaced with the equivalent potency of risperidone (maximum dose was 12 mg/day) in 2 weeks, based on the antipsychotics conversion table by the Treatment Resistant Schizophrenia Research Group of the Japanese Ministry of Health and Welfare.
Clinical symptoms initially and after 8 weeks of treatment were evaluated using PANSS. 28 Psychiatrists and clinical psychologists, who were well trained, performed the PANSS assessments. ) were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A volume of 7 ml of EDTA-anticoagulated venous blood sample was drawn from each subject, and DNA was isolated from leukocytes using the PUREGENEt DNA isolation kit (Gentra Systems, Minneapolis, MN USA). All genotyping methods were followed by the previous descriptions. 3, 4, 17, 29, 30 Statistical Analysis Statistical analysis to evaluate the differences between groups was carried out by either Fisher's exact test for discrete data or by Mann-Whitney's test for continuous data.
Laboratory Methods
Deviation from the genotype counts predicted by HardyWeinberg equilibrium expectations was tested using an exact test, as described by Weir 31 and implemented in the software written by Lewis and Zaykin (2001; Genetic Data Analysis (GDA), version 1.0 (d16c)).
Estimation of the haplotype frequencies was performed by the expectation-maximization (EM) algorithm, a pseudoGibbs sampler (PGS) algorithm, and a partition ligation (PL) algorithm. Haplotyper, 15 which implements the PL algorithm, was kindly provided by T Niu. PHASE, 16 which implements the PGS algorithm as described by Stephens et al, was downloaded from their website (Mathematics Genetics Group). EM-Decoder, 15 which implements the EM algorithm as described by Niu et al, was downloaded from their website. The genetic status of an individual concerning linked loci can be expressed by the combination of two haplotypes (diplotype configuration).
The total and subscale scores of PANSS were used as a measure of response to risperidone. The potential prognostic factors included DRD2 diplotype, HTR2A diplotype, and COMT genotype, as well as the administrated group (New or Switched), gender, age at illness onset, duration of illness, number of previous hospitalizations, baseline PANSS total score, and endpoint risperidone dose. As there were repeated assessments, multiple linear regressions were used to adjust the within-subject dependence. Statistical significance was DRD2, HTR2A, COMT, and risperidone treatment response Y Yamanouchi et al
